QQ客服 官方微博 反馈留言

	Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma.
	Guo, Jun; Cui, Chuan Liang; Gu, Kangsheng; Tao, Min; Xin, Song; Lin, Tongyu; Ren, Xiu Bao; Qin, Shukui
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2012
卷号	30期号:15
ISSN号	0732-183X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3449862
专题	昆明医科大学
推荐引用方式 GB/T 7714	Guo, Jun,Cui, Chuan Liang,Gu, Kangsheng,et al. Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma.[J]. JOURNAL OF CLINICAL ONCOLOGY,2012,30(15).
APA	Guo, Jun.,Cui, Chuan Liang.,Gu, Kangsheng.,Tao, Min.,Xin, Song.,...&Qin, Shukui.(2012).Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma..JOURNAL OF CLINICAL ONCOLOGY,30(15).
MLA	Guo, Jun,et al."Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma.".JOURNAL OF CLINICAL ONCOLOGY 30.15(2012).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。